The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
ApexOnco Front Page
Recent articles
The company discontinues its Yap/TEAD inhibitor IAG933 due to lack of tolerability and efficacy.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Artios, Synnovation and Novartis show mere glimmers of activity.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
Boehringer’s Hernexeos and Bayer’s sevabertinib look similar in first-line HER2-mutant NSCLC.
